MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

Rating neurologic impairment in multiple sclerosis

1983 • 14,011 citations

Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction

1989 • 3,227 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Surrogate endpoints in clinical trials: Definition and operational criteria

1989 • 1,929 citations

Surrogate End Points in Clinical Trials: Are We Being Misled?

1996 • 1,592 citations

Relapses and Progression of Disability in Multiple Sclerosis

2000 • 1,285 citations

Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis

1998 • 931 citations

Interferon beta‐lb in the treatment of multiple sclerosis

1995 • 899 citations

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

2001 • 697 citations

Statistical validation of intermediate endpoints for chronic diseases

1992 • 629 citations

European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

2001 • 595 citations

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

1998 • 553 citations

The validation of surrogate endpoints in meta-analyses of randomized experiments

2000 • 545 citations

ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER

1997 • 483 citations

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis

1996 • 444 citations

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

2000 • 422 citations

Criteria for the Validation of Surrogate Endpoints in Randomized Experiments

1998 • 416 citations

SERIAL GADOLINIUM ENHANCED MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS

1988 • 397 citations

Diagnostic criteria for primary progressive multiple sclerosis: a position paper.

2000 • 349 citations

Meta-analysis for the evaluation of potential surrogate markers

1997 • 333 citations

Diagnostic criteria for primary progressive multiple sclerosis: A position paper

2000 • 300 citations

Surrogate endpoints in clinical trials: Cardiovascular diseases

1989 • 235 citations

Evidence of interferon β-1a dose response in relapsing-remitting MS

1999 • 201 citations

CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine

1993 • 197 citations

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

1998 • 166 citations

Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis

1998 • 157 citations

ON THE RELATIONSHIP BETWEEN RESPONSE TO TREATMENT AND SURVIVAL TIME

1996 • 130 citations

Perspective: Validating Surrogate Markers--Are We Being Naive?

1997 • 125 citations

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis

1997 • 105 citations

Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis

1999 • 87 citations

Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials

1999 • 77 citations

Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials

1997 • 68 citations

The role of MRI as a surrogate outcome measure in multiple sclerosis

2002 • 45 citations